行情

XNCR

XNCR

Xencor
NASDAQ

实时行情|Nasdaq Last Sale

30.25
-0.75
-2.42%
已收盘, 16:25 05/29 EDT
开盘
30.83
昨收
31.00
最高
31.00
最低
29.27
成交量
44.12万
成交额
--
52周最高
46.33
52周最低
19.35
市值
17.24亿
市盈率(TTM)
-27.9937
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XNCR价格均价为44.17,最高价位56.00,最低价为21.00。

EPS

XNCR 新闻

更多
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 2天前
Edited Transcript of XNCR earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Xencor Inc Earnings Call
Thomson Reuters StreetEvents · 3天前
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will par
Business Wire · 5天前
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Benzinga · 05/24 18:40
Xencor to Present Data from Four Preclinical XmAb 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR) announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody programs and an IL-12-Fc cytokine program at the second session of the American Association for Cancer Research (AACR) Virtual Annual Meeting, bei
Benzinga · 05/15 09:27
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody
Business Wire · 05/15 04:01
Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb In Solid Tumors: 'generally well-tolerated and a confirmed complete response observed at highest dose level tested'
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the
Benzinga · 05/13 21:10
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®20717, a
Business Wire · 05/13 21:00

所属板块

生物技术和医学研究
+1.44%
制药与医学研究
+1.29%

热门股票

代码
价格
涨跌幅

XNCR 简况

Xencor, Inc.是一家临床阶段的生物制药公司。该公司专注于发现和开发单克隆抗体,以治疗严重的和危及生命的疾病。其部门从事医药产品的开发业务。它使用其XmAb技术平台来创建抗体候选产品,以治疗自身免疫和过敏性疾病、癌症和其他病况。其临床阶段候选产品包括正在开发的XmAb5871和XmAb7195。XmAb5871用于治疗自身免疫疾病。XmAb7195用于治疗哮喘和过敏性疾病。其临床前阶段的肿瘤候选产品包括XmAb14045和XmAb13676。除了其临床开发阶段的化合物,该公司使用XmAb技术来生产抗体化合物。这些化合物被授权给其他制药和生物技术公司进一步开发,包括XmAb5574 / MOR208和XmAb13551。
展开

微牛提供Xencor Inc(NASDAQ-XNCR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XNCR股票新闻,以帮助您做出投资决策。